BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Minerva Neurosciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Minerva Neurosciences's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07565428-9264@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Roluperidone: Phase 3 readout est. (NCT07565428)
DESCRIPTION:Roluperidone\, phase 3\, Schizophrenia.\nStudy: Study to Evalua
 te Efficacy and Safety of Roluperidone in Adult Subjects With Negative Sym
 ptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Re
 lapse Rate of Roluperidone and Antipsychotic Medications\nEstimated primar
 y completion: December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/roluperidone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07565428
URL:https://assetmemo.bio/drug/roluperidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
